标题
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
作者
关键词
Imatinib, Irinotecan, Cetuximab, Gefitinib, Busulfan
出版物
CLINICAL PHARMACOKINETICS
Volume 56, Issue 4, Pages 317-337
出版商
Springer Nature
发表日期
2016-09-19
DOI
10.1007/s40262-016-0450-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy
- (2016) Maurice C. van Staveren et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma
- (2016) Gareth J. Veal et al. EUROPEAN JOURNAL OF CANCER
- Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer
- (2016) Takashi Hirose et al. LUNG CANCER
- Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients
- (2016) Patricia Moya et al. PHARMACOGENOMICS
- Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy
- (2015) Lin Mei et al. BLOOD REVIEWS
- Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity
- (2015) Kayode Ogungbenro et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review
- (2015) Francesca De Iuliis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations
- (2015) Christian Queckenberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Personalizing chemotherapy dosing using pharmacological methods
- (2015) Jai N. Patel et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans
- (2015) Kyoung-Ah Kim et al. CLINICA CHIMICA ACTA
- Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non–Small-Cell Lung Cancer
- (2015) Hiroyuki Kobayashi et al. Clinical Lung Cancer
- Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis
- (2015) David Ternant et al. CLINICAL PHARMACOKINETICS
- Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease
- (2015) Mehmet Coskun et al. CLINICAL PHARMACOKINETICS
- Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
- (2015) Aurelia H. M. de Vries Schultink et al. CLINICAL PHARMACOKINETICS
- CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
- (2015) Meta H.M. Diekstra et al. EUROPEAN UROLOGY
- Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease
- (2015) Marieke J.H. Coenen et al. GASTROENTEROLOGY
- Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
- (2015) Marialuisa Polillo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
- (2015) Didier Meulendijks et al. LANCET ONCOLOGY
- Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
- (2015) L Lu et al. LEUKEMIA
- High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study
- (2015) S. Manfredi et al. MOLECULAR CANCER THERAPEUTICS
- Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale
- (2015) Raphaelle Fanciullino et al. PHARMACOGENOMICS
- Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity
- (2015) Dominic Kummer et al. PHARMACOGENOMICS
- FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
- (2014) Janne B Kjersem et al. BMC CANCER
- Associations of novel genetic variations in the folate-related andARID5Bgenes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia
- (2014) Katalin Csordas et al. BRITISH JOURNAL OF HAEMATOLOGY
- Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics
- (2014) Lynne Lennard et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy
- (2014) Jessica Mwinyi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration
- (2014) Jeannine S. McCune et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group
- (2014) Patrick Thompson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
- (2014) Clinton F. Stewart et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
- (2014) David Jamieson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic Properties of Two Erlotinib 150 mg Formulations with a Genetic Effect Evaluation in Healthy Korean Subjects
- (2014) Hyun-Gyu Choi et al. CLINICAL DRUG INVESTIGATION
- Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer
- (2014) Christopher R. Hill et al. CLINICAL PHARMACOKINETICS
- Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease
- (2014) David Ternant et al. CLINICAL PHARMACOKINETICS
- Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662
- (2014) M H M Diekstra et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
- (2014) Patricia Huezo-Diaz et al. CURRENT DRUG METABOLISM
- Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics
- (2014) M.H. ten Brink et al. DRUG DISCOVERY TODAY
- Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs
- (2014) Cindy Serdjebi et al. Expert Opinion on Drug Metabolism & Toxicology
- FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study
- (2014) Ravit Geva et al. GUT
- Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
- (2014) Tanja K. Froehlich et al. INTERNATIONAL JOURNAL OF CANCER
- Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to theUGT1A1Genotype of Patients With Cancer
- (2014) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
- (2014) Dan Rosmarin et al. JOURNAL OF CLINICAL ONCOLOGY
- DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)
- (2014) Adam M. Lee et al. JNCI-Journal of the National Cancer Institute
- Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia
- (2014) Jacob Vine et al. LEUKEMIA & LYMPHOMA
- The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients
- (2014) Murtala B. Abubakar et al. Pharmacogenetics and Genomics
- Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers
- (2014) Aurea Lima et al. PHARMACOGENOMICS
- The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia
- (2014) A Di Paolo et al. PHARMACOGENOMICS JOURNAL
- ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib
- (2014) DOUGLAS VIVONA et al. Oncology Letters
- Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
- (2014) Ãngela Roco et al. Frontiers in Genetics
- CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia
- (2013) G. G. Johnson et al. BLOOD
- Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia
- (2013) S. Radtke et al. BLOOD
- Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer
- (2013) Sook Ryun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
- (2013) R. Z. Mahfouz et al. CLINICAL CANCER RESEARCH
- Molecular Basis for Pharmacokinetics and Pharmacodynamics of Methotrexate in Rheumatoid Arthritis Therapy
- (2013) Katsuhisa Inoue et al. Drug Metabolism and Pharmacokinetics
- Influence ofFCGRTgene polymorphisms on pharmacokinetics of therapeutic antibodies
- (2013) Christophe Passot et al. mAbs
- Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity
- (2013) Jonathan Knights et al. Pharmacogenetics and Genomics
- PharmGKB summary
- (2013) Julia M. Barbarino et al. Pharmacogenetics and Genomics
- DPYDIVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis
- (2013) Salvatore Terrazzino et al. PHARMACOGENOMICS
- Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy
- (2013) Liming Weng et al. PHARMACOGENOMICS
- The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation
- (2013) C R S Uppugunduri et al. PHARMACOGENOMICS JOURNAL
- Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
- (2013) Metin Karahoca et al. Clinical Epigenetics
- Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
- (2012) S. J. Seong et al. ANNALS OF ONCOLOGY
- ß-Ureidopropionase deficiency: Phenotype, genotype and protein structural consequences in 16 patients
- (2012) André B.P. van Kuilenburg et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Influence of Cytochrome P450 2C19 Gene Variations on Pharmacokinetic Parameters of Thalidomide in Japanese Patients
- (2012) Naoki Matsuzawa et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- PHASE II DRUG METABOLIZING ENZYMES
- (2012) Petra Jancova et al. BIOMEDICAL PAPERS-OLOMOUC
- Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
- (2012) Mikkel Krogh-Madsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor
- (2012) V. Gouilleux-Gruart et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Analysis of Fc Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
- (2012) S. A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Evaluation of 5-Fluorouracil Pharmacokinetics in Cancer Patients with a C.1905+1G>A Mutation in DPYD by Means of a Bayesian Limited Sampling Strategy
- (2012) André B. P. van Kuilenburg et al. CLINICAL PHARMACOKINETICS
- Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
- (2012) Javier Rodríguez et al. EUROPEAN JOURNAL OF CANCER
- Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia
- (2012) Tiphaine Adam de Beaumais et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenomics of third-generation aromatase inhibitors
- (2012) Abdullah Turkistani et al. EXPERT OPINION ON PHARMACOTHERAPY
- Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
- (2012) D. O. Persky et al. HAEMATOLOGICA
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country
- (2012) Gauri Kapoor et al. PEDIATRIC BLOOD & CANCER
- Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
- (2012) Pascaline Boudou-Rouquette et al. PLoS One
- The impact of Fc- receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
- (2011) M. Ahlgrimm et al. BLOOD
- Q172H Replacement Overcomes Effects on the Metabolism of Cyclophosphamide and Efavirenz Caused by CYP2B6 Variant with Arg262
- (2011) N. Ariyoshi et al. DRUG METABOLISM AND DISPOSITION
- Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast Cancer Resistance Protein) on the Oral Pharmacokinetics of Methotrexate and Its Main Metabolite 7-Hydroxymethotrexate
- (2011) M. L. H. Vlaming et al. DRUG METABOLISM AND DISPOSITION
- Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2)
- (2011) Ichiro Ieiri Drug Metabolism and Pharmacokinetics
- Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma
- (2011) Barbara Faganel Kotnik et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics
- (2011) Meghan Brennan et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
- (2011) L. B. Ramsey et al. GENOME RESEARCH
- Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism
- (2011) M. J. Deenen et al. ONCOLOGIST
- Association analysis ofCYP2A6genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes
- (2011) Huijuan Wang et al. PHARMACOGENOMICS
- Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
- (2010) K. Tamura et al. ANNALS OF ONCOLOGY
- Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients
- (2010) André B.P. van Kuilenburg et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring
- (2010) J. Gaziev et al. BLOOD
- No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
- (2010) Annette J Vangsted et al. BMC CANCER
- Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer
- (2010) Peter L. Bonate et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases
- (2010) Romain Guilhaumou et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism
- (2010) Jan Gerard Maring et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics of Clofarabine in Patients With High-Risk Inherited Metabolic Disorders Undergoing Brain-Sparing Hematopoietic Cell Transplantation
- (2010) Janel Long-Boyle et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia
- (2010) Naoto Takahashi et al. JOURNAL OF HUMAN GENETICS
- Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
- (2010) Hirose ONCOLOGY REPORTS
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma
- (2009) David I. Quinn et al. CLINICAL PHARMACOKINETICS
- Clinical pharmacology and pharmacogenetics of gemcitabine
- (2009) Andrea Wong et al. DRUG METABOLISM REVIEWS
- UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
- (2009) Masahide Onoue et al. International Journal of Clinical Oncology
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects
- (2009) Lisa R. Treviño et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies
- (2009) Joseph Ciccolini et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
- (2009) Giuseppe Toffoli et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma
- (2009) Wen-Kai Weng et al. JOURNAL OF CLINICAL ONCOLOGY
- Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma
- (2009) Mehmet Kantar et al. LEUKEMIA & LYMPHOMA
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Taxane pathway
- (2009) Connie Oshiro et al. Pharmacogenetics and Genomics
- Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
- (2008) S. Dulucq et al. BLOOD
- Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia
- (2008) Ahmed F. Hawwa et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa
- (2008) Corine Ekhart et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients
- (2008) Suman Lal et al. CANCER SCIENCE
- An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment
- (2008) Corine Ekhart et al. CANCER TREATMENT REVIEWS
- Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults
- (2008) A. Petain et al. CLINICAL CANCER RESEARCH
- Variation in Bleomycin Hydrolase Gene Is Associated With Reduced Survival After Chemotherapy for Testicular Germ Cell Cancer
- (2008) Esther C. de Haas et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene
- (2008) A. B. P. van Kuilenburg et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Genetic regulation of ??-ureidopropionase and its possible implication in altered uracil catabolism
- (2008) Holly R. Thomas et al. Pharmacogenetics and Genomics
- Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin
- (2008) Corine Ekhart et al. Pharmacogenetics and Genomics
- Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide
- (2008) Corine Ekhart et al. Pharmacogenetics and Genomics
- Pharmacogenetics of Gilbert’s syndrome
- (2008) Christian P Strassburg PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started